Consensus Statement on Hemostatic Management, Anticoagulation, and Antiplatelet Therapy in Liver Transplantation
Authors:
- Manuel Rodríguez-PerálvarezManuel Rodríguez-Perálvarez
- Jordi ColmeneroJCJordi Colmenero
- On Behalf Of The Spanish Society Of Liver Transplantation And The Spanish Society Of Thrombosis And HaemostasisOHOn Behalf Of The Spanish Society Of Liver Transplantation And The Spanish Society Of Thrombosis And Haemostasis
Open Access
- 4 January 2022
- journal article
- review article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 106 (6) , 1123-1131
Abstract
Anticoagulation and antiplatelet therapies are increasingly used in liver transplant (LT) candidates and recipients due to cardiovascular comorbidities, portal vein thrombosis, or to manage posttransplant complications. The implementation of the new direct-acting oral anticoagulants and the recently developed antiplatelet drugs is a great challenge for transplant teams worldwide, as their activity must be monitored and their complications managed, in the absence of robust scientific evidence. In this changing and clinically heterogeneous scenario, the Spanish Society of Liver Transplantation and the Spanish Society of Thrombosis and Haemostasis aimed to achieve consensus regarding the indications, drugs, dosing, and timing of anticoagulation and antiplatelet therapies initiated from the inclusion of the patient on the waiting list to post-LT surveillance. A multidisciplinary group of experts composed by transplant hepatologists, surgeons, hematologists, transplant-specialized anesthesiologists, and intensivists performed a comprehensive review of the literature and identified 21 clinically relevant questions using the patient-intervention-comparison-outcome format. A preliminary list of recommendations was drafted and further validated using a modified Delphi approach by a panel of 24 transplant delegates, each representing a LT institution in Spain. The present consensus statement contains the key recommendations together with the core supporting scientific evidence, which will provide guidance for improved and more homogeneous clinical decision making.Keywords
This publication has 97 references indexed in Scilit:
- Management of Antithrombotic Therapy in Patients Undergoing Invasive ProceduresNew England Journal of Medicine, 2013
- Antithrombotic Therapy for VTE DiseaseChest, 2012
- Prevention of VTE in Nonorthopedic Surgical PatientsChest, 2012
- Oral Anticoagulant TherapyChest, 2012
- Portal vein thrombosis and liver transplant survival benefitLiver Transplantation, 2010
- Risk of Complications After Abdominal Paracentesis in Cirrhotic Patients: A Prospective StudyClinical Gastroenterology and Hepatology, 2009
- Going from evidence to recommendationsBMJ, 2008
- Risks and benefits of transcatheter thrombolytic therapy in patients with splanchnic venous thrombosisThrombosis and Haemostasis, 2008
- Clinical presentation and time-course of postoperative venous thromboembolism: Results from the RIETE RegistryThrombosis and Haemostasis, 2008
- Efficacy and Safety of Antifibrinolytic Drugs in Liver Transplantation: A Systematic Review and Meta-AnalysisAmerican Journal of Transplantation, 2007